\
&
Contact us
\
&
Contact us
Published on | 5 months ago
ProgrammesThe European Commission intends to cancel three quantum topics from the Horizon Europe Cluster 4 work programme 2026-2027. The topics in call HORIZON-CL4-2026-04 are currently suspended while an amendment to the work programme is being finalised, which is currently foreseen in the fourth quarter of 2026. The submission platform for these topics is no longer accessible, and participants preparing or submitting proposals have already been informed.
The European Commission decided to cancel three quantum topics from the Horizon Europe Cluster 4 work programme 2026-2027. The topics in call HORIZON-CL4-2026-04 are currently suspended while an amendment to the work programme is being finalised, which is currently foreseen in the fourth quarter of 2026. The submission platform for these topics is no longer accessible, and participants preparing or submitting proposals have already been informed.
The intention is to relaunch these call topics under the EuroHPC Joint Undertaking, which will be mandated to include, among other things, also quantum technologies.
The suspended topics are
Further information is expected from EuroHPC JU, including updates on possible future calls: https://eurohpc-ju.europa.eu and https://eurohpc-ju.europa.eu/about-eurohpc-ju_en.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
